Athira Pharma

Athira Pharma is a clinical stage American therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer's disease and Parkinson's disease.[1] The company's main product is in very early human studies for Alzheimer's disease as of 2019.[2]

Athira Pharma
IndustryBiotechnology, Pharmaceuticals
Founded2011
Headquarters
Seattle
,
United States
ProductsNDX-1017
Websitewww.athira.com

The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.[3][4][5][6]

Leen Kawas currently serves as the company's President and CEO.[7]

History

The company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date. [8] Athira Pharma was known as M3 Biotechnology until it underwent a name change on April 11, 2019.[9]

Core technology

The company's lead asset, NDX-1017, is in very early human trials of Alzheimer's disease as of 2019.[2] It aims to regenerate lost connections in the brain, protect brain cells from further damage, and prevent additional neuronal deterioration. [10]

gollark: Presumably the idea is that the contact tracing apps would keep it turn on, and people would have to suffer the slightly higher battery drain.
gollark: https://www.eff.org/deeplinks/2020/04/challenge-proximity-apps-covid-19-contact-tracing
gollark: The rough idea of the decent-for-privacy idea is apparently to have each phone have a unique ID (or one which changes periodically or something, presumably it would store all its past ones), and devices which are near each other (determined via Bluetooth signal strength apparently) for some amount of time exchange identifiers, and transmit in some way the IDs of devices of people who get inected.
gollark: I see.
gollark: What's that using, then?

References
  1. "M3 Biotechnology Company Profile: Valuation & Investors | PitchBook". pitchbook.com. Retrieved 2018-10-15.
  2. "NDX-1017 in Healthy Volunteers and People with Mild Alzheimer's". National Institute on Aging. Retrieved 15 April 2019.
  3. "ADDF Funding Advances M3 Biotechnology Toward Clinical Trials | Alzheimer's Drug Discovery Foundation". www.alzdiscovery.org. Retrieved 2018-10-15.
  4. "First Trial of Alzheimer's Drug Underway | Science and Enterprise". sciencebusiness.technewslit.com. Retrieved 2018-10-15.
  5. "Individual Grants | Life Sciences Discovery Fund". www.lsdfa.org. Retrieved 2018-07-31.
  6. "W Fund | Crunchbase". Crunchbase. Retrieved 2018-07-31.
  7. "Entrepreneurship has grown on M3 Biotechnology's CEO". The Seattle Times. 2017-04-30. Retrieved 2018-07-31.
  8. "M3 Biotechnology Company Profile: Valuation & Investors | PitchBook". pitchbook.com. Retrieved 2018-10-15.
  9. Inc, Athira Pharma. "M3 Biotechnology Announces Name Change to Athira Pharma, Inc". www.prnewswire.com. Retrieved 2019-04-15.
  10. "M3 Biotechnology Launches Clinical Trials for Alzheimer's Disease Drug Focused on Restoring Lost Connections in the Brain". Retrieved 2018-10-15.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.